BridgeBio Pharma, Inc. BBIO

US Biotechnology

$77.93 ▲ +4.90% (+$3.64)

Open $74.58

Prev Close $74.29

Day Range $73.49 – $78.06

52W Range $60.55 – $93.42

Market Cap $15.18B

Beta 1.12

EPS (TTM) $-2.91

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2019-06-27
Shares Out.	194,800,000
Website	bridgebio.com/ ↗
Phone	13026587581
Employees	839
Revenue	$353.2M
Gross Profit	$332.7M
Net Income	-$60.5M
Free Cash Flow	-$369.8M
Total Assets	$2.16B
Total Liabilities	$3.82B
Equity	-$1.65B

About BridgeBio Pharma, Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. Its key drug is Attruby (acoramidis), an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

BridgeBio Pharma, Inc. is a publicly traded company under the ticker symbol BBIO on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.